Part A: RPL554

DRUG2 trials

Sponsors

Verona Pharma plc

Conditions

COPDPulmonary Disease, Chronic Obstructive

Phase 2

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

CompletedNCT04027439

Verona Pharma plcPulmonary Disease, Chronic Obstructive

Start: 2018-12-10End: 2019-05-23Updated: 2022-09-26

A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

CompletedNCT04091360

Verona Pharma plcCOPD

Start: 2019-04-29End: 2021-01-21Updated: 2022-09-21